Colorado SB26-066 creates a new regulatory framework layered on top of an already robust system that threatens patient access to care, rather than improving safety. Recent narratives from large pharmaceutical manufacturers have dangerously conflated two entirely different issues: the illegal sale of fake drugs and the legitimate medical practice of pharmacy compounding.
The black market of illegal counterfeiters and the highly regulated, safety-focused reality of licensed compounding should not be treated the same as opponents would suggest.
.png)
Compounding pharmacies do not replace or undermine pharmaceutical innovation; they serve patients whose clinical needs are not met by FDA-approved products. Federal law has long recognized compounding as a complementary, patient-specific practice that relies on prescriber judgment. The value compounders provide is access and customization.
Compounding allows pharmacists to meet legitimate patient needs when:
Many medications, including GLP-1s, have experienced sustained supply disruptions and high costs. Prescription-based 503A compounding enables pharmacists to help patients maintain continuity of care within a regulated framework.
1. Manufacturer-Level Compliance Requirements for Pharmacies
The bill forces pharmacies to perform FDA-level compliance functions — NDA verification, inspection classification review, and impurity analysis — tasks designed for manufacturers, not community pharmacies.
2. Mandatory Labeling Language
Required language claims compounded drugs have “no evidence of safety or efficacy,” going beyond federal standards and potentially overstating risk without evidence. It raises constitutional concerns and could mislead patients.
3. Advertising Restrictions
The bill applies manufacturer-level and clinical-trial standards to pharmacy communication. It also requires the compounder to disclose risks associated with the FDA approved drug. Compounding pharmacies do not conduct large-scale clinical trials and are not structured like pharmaceutical manufacturers and cannot meet these requirements.
4. Expanded Inspection Authority
The bill authorizes inspections not only by the Board of Pharmacy, but also by its agents and third-party agents approved by the Board. This extends oversight beyond traditional pharmacy inspection frameworks and could lead to overreach.
5. Enforcement Structure
Fines of up to $1,000 per vial, license revocation, and Attorney General enforcement are excessive. In practice, this bill will put pharmacies out of business, limiting patient access to care.
Patient safety is enforced through state licensure, inspection, adverse-event reporting, professional liability, and adherence to a multitude of standards. Prescribers and pharmacists remain directly accountable to patients—often with more individualized monitoring than mass-market drugs. This is active clinical oversight and accountability, not deregulation.
We urge Colorado lawmakers to stand with patients and protect pharmacy compounding by opposing SB26-066.
